Company type | Aktieselskab |
---|---|
Industry | Pharmaceuticals, health care [1] |
Founded | 1958 [1] |
Headquarters | Copenhagen, Denmark [1] |
Website | http://www.xellia.com |
Xellia ApS is a Danish multinational pharmaceutical and life sciences company headquartered in Copenhagen [1] specialized in the production of anti-biotics, including Vancomycin [2] and Bacitracin. [3]
The company's US base of operations is in Buffalo Grove, Illinois, [4] [5] with additional facilities in Ohio, and North Carolina. [6] [7] In 2018, Xellia's sales in the United States accounted for 60% of its total revenue. [5]
The company's main output is bulk drug chemicals which are wholesaled to other companies for packaging and distribution. Recently some prepackaged goods have been produced.
Active drug substances manufactured are: [8]
ATC | Substance | Structural formula | Formulation for sale | Production started |
---|---|---|---|---|
D06AX05 (WHO) (FK) J01XX10 (WHO) (FK) R02AB04 (WHO) (FK) QA07AA93 (WHO) (FK) | Bacitracin (MT) [9] [10] | ![]() | Bacitracin | 1952 |
D06AX05 (WHO) (FK) J01XX10 (WHO) (FK) R02AB04 (WHO) (FK) QA07AA93 (WHO) (FK) | Bacitracin (MT) [9] [10] | ![]() | Bacitracin zinc | 1958 |
Colistimethate natrium (CMS) | ||||
A07AA10 (WHO) (FK) J01XB01 (WHO) (FK) QJ51XB01 (WHO) (FK) | Colistin | ![]() | Colistin sulfate | 1969 |
J01X X09 | Daptomycin (MT) [9] [11] | ![]() | Daptomycin | |
R02AB30 (WHO) (FK) | ![]() | Gramicidin | ||
A07AA05 (WHO) (FK) J01XB02 (WHO) (FK) S01AA18 (WHO) (FK) S02AA11 (WHO) (FK) S03AA03 (WHO) (FK) QJ51XB02 (WHO) (FK) | Polymyxin B (MT) [9] [12] | ![]() | Polymyxin B-sulfate | 1968 |
J01GB01 (WHO) (FK) S01AA12 (WHO) (FK) | Tobramycin (MT) [9] [13] | ![]() | Tobramycin sulfate | 2005 |
D06AX08 (WHO) (FK) R02AB02 (WHO) (FK) S01AA05 (WHO) (FK) | Tyrothricin | ![]() | Tyrothricin | |
A07AA09 (WHO) (FK) J01XA01 (WHO) (FK) | Vancomycin (MT) [9] [14] | ![]() | Vancomycin hydrochloride | 2003 |
A01AB04 (WHO) (FK) A07AA07 (WHO) (FK) G01AA03 (WHO) (FK) J02AA01 (WHO) (FK) | Amfotericin B (MT) [9] [15] | ![]() | Amfotericin B | 1985 |
J02AX04 (WHO) (FK) | Caspofungin (MT) [9] [16] | ![]() | Caspofungin acetate | |
D07AC17 (WHO) (FK) R01AD08 (WHO) (FK) R01AD58 (WHO) (FK) R03BA05 (WHO) (FK) | Fluticasone (MT) [9] [17] | ![]() | Fluticasone propionate | |
D07AC13 (WHO) (FK) R01AD09 (WHO) (FK) R03BA07 (WHO) (FK) | Mometasone (MT) [9] [18] | ![]() | Mometasone furoate |
Previously the company also produced:
Ingredient | Produced |
---|---|
Neomycin | 1952-? |
Tetracycline | 1961-? |
In 2019, Xellia partnered with Civica Rx to produce generic Vancomycin and Daptomycin. The partnership's stated aim is to remedy chronic drug shortages that have affected the American pharmaceutical market. [4] [19] [20] [21] [22]
Xellia has been discussed as a potential alternative to Chinese companies for anti-biotic primary ingredients in the context of the China-United States trade war. [23]